TW201513882A - 抗－催乳激素受體抗體調配物 - Google Patents

抗－催乳激素受體抗體調配物 Download PDF

Info

Publication number
TW201513882A
TW201513882A TW103109457A TW103109457A TW201513882A TW 201513882 A TW201513882 A TW 201513882A TW 103109457 A TW103109457 A TW 103109457A TW 103109457 A TW103109457 A TW 103109457A TW 201513882 A TW201513882 A TW 201513882A
Authority
TW
Taiwan
Prior art keywords
prlr antibody
prlr
antibody formulation
antibody
formulation
Prior art date
Application number
TW103109457A
Other languages
English (en)
Chinese (zh)
Inventor
Xing-Hang Ma
Jian-Jie Niu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TW201513882A publication Critical patent/TW201513882A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW103109457A 2013-03-15 2014-03-14 抗－催乳激素受體抗體調配物 TW201513882A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
TW201513882A true TW201513882A (zh) 2015-04-16

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103109457A TW201513882A (zh) 2013-03-15 2014-03-14 抗－催乳激素受體抗體調配物

Country Status (10)

Country Link
US (2) US9023357B2 (https=)
EP (1) EP2968538A1 (https=)
JP (1) JP2016515515A (https=)
CN (1) CN105025925A (https=)
AR (1) AR095496A1 (https=)
CA (1) CA2906101A1 (https=)
HK (1) HK1215175A1 (https=)
TW (1) TW201513882A (https=)
UY (1) UY35460A (https=)
WO (1) WO2014143909A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
MX2018007520A (es) 2015-12-18 2018-08-01 Astellas Pharma Inc Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
KR20180106974A (ko) * 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
KR20250120995A (ko) 2022-11-07 2025-08-11 업스트림 바이오, 인크. 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR062435A1 (es) * 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
US20100189723A1 (en) * 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
PE20110302A1 (es) 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations

Also Published As

Publication number Publication date
HK1215175A1 (zh) 2016-08-19
CN105025925A (zh) 2015-11-04
AR095496A1 (es) 2015-10-21
US20160002342A1 (en) 2016-01-07
US20140271659A1 (en) 2014-09-18
EP2968538A1 (en) 2016-01-20
US9023357B2 (en) 2015-05-05
UY35460A (es) 2014-10-31
WO2014143909A1 (en) 2014-09-18
JP2016515515A (ja) 2016-05-30
CA2906101A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
EP2890397B1 (en) Anti-prolactin receptor antibody formulations
TW201513882A (zh) 抗－催乳激素受體抗體調配物
JP5631591B2 (ja) 安定な抗体製剤
US20150044206A1 (en) Immunoglobulin formulation and method of preparation thereof
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
HK40020980A (en) Anti-prolactin receptor antibody formulations
HK40020981A (en) Anti-prolactin receptor antibody formulations
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
TW202237185A (zh) Ｈｅｒ２／ｎｅｕ抗體的藥物組合物及其用途
HK1207316B (zh) 抗催乳素受体抗体制剂